Raymond James Reinstates Outperform on Agios Pharmaceuticals, Announces $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and set a price target of $51.
October 10, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Agios Pharmaceuticals with a $51 price target, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating and a specific price target of $51 by a reputable analyst can boost investor confidence and potentially lead to a short-term increase in AGIO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100